- Home
- RSLS vs MYNZ Comparison
RSLS vs MYNZ Comparison
Compare RSLS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- MYNZ
- Stock Information
- Founded
- RSLS 2002
- MYNZ 2021
- Country
- RSLS United States
- MYNZ Germany
- Employees
- RSLS N/A
- MYNZ N/A
- Industry
- RSLS Medical/Dental Instruments
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- MYNZ Health Care
- Exchange
- RSLS Nasdaq
- MYNZ Nasdaq
- Market Cap
- RSLS 5.7M
- MYNZ 5.1M
- IPO Year
- RSLS 2007
- MYNZ 2021
- Fundamental
- Price
- RSLS $2.58
- MYNZ $1.52
- Analyst Decision
- RSLS
- MYNZ Buy
- Analyst Count
- RSLS 0
- MYNZ 2
- Target Price
- RSLS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- RSLS 458.6K
- MYNZ 228.6K
- Earning Date
- RSLS 08-18-2025
- MYNZ 08-12-2025
- Dividend Yield
- RSLS N/A
- MYNZ N/A
- EPS Growth
- RSLS N/A
- MYNZ N/A
- EPS
- RSLS N/A
- MYNZ N/A
- Revenue
- RSLS $7,175,000.00
- MYNZ $893,991.00
- Revenue This Year
- RSLS $52.80
- MYNZ $26.06
- Revenue Next Year
- RSLS N/A
- MYNZ $4.97
- P/E Ratio
- RSLS N/A
- MYNZ N/A
- Revenue Growth
- RSLS N/A
- MYNZ N/A
- 52 Week Low
- RSLS $2.23
- MYNZ $1.30
- 52 Week High
- RSLS $303.25
- MYNZ $18.40
- Technical
- Relative Strength Index (RSI)
- RSLS 45.22
- MYNZ 40.33
- Support Level
- RSLS $2.35
- MYNZ $1.30
- Resistance Level
- RSLS $2.56
- MYNZ $2.07
- Average True Range (ATR)
- RSLS 0.25
- MYNZ 0.19
- MACD
- RSLS 0.05
- MYNZ -0.05
- Stochastic Oscillator
- RSLS 21.77
- MYNZ 21.19
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.